Stoke Therapeutics is a developer of antisense oligonucleotide medicines that target ribonucleic acid (RNA) splicing to enhance gene expression for the treatment of genetic diseases. The company focuses on an array of genetic disorders affecting the central nervous system, eyes, liver, and kidneys. Its portfolio includes a disease-modifying therapy for Dravet syndrome, a severe and progressive genetic epilepsy.